Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. Anavex is currently in a Phase 2a trial for Alzheimer's disease (AD) with lead therapeutic, ANAVEX 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the Sigma-1 Receptor. PART A topline data of our ongoing Phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. ANAVEX 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: Rett syndrome, as well is in epilepsy and multiple sclerosis (MS). In 2015, the Company was awarded a research by the Michael J. Fox Foundation (MJFF) to study ANAVEX 2-73 for the treatment of Parkinson’s disease. Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.